Vaccinia Virus News and Research

RSS
The vaccinia virus is the "live virus" used in the smallpox vaccine. It is a "pox"-type virus related to smallpox. When given to humans as a vaccine, it helps the body to develop immunity to smallpox. The smallpox vaccine does not contain the smallpox virus and it cannot cause smallpox.
Common DNA variations underlie susceptibility to fever after smallpox vaccination

Common DNA variations underlie susceptibility to fever after smallpox vaccination

Genetic factors linked to adverse events related to smallpox vaccination

Genetic factors linked to adverse events related to smallpox vaccination

Bioinformatics used to advance human disease research

Bioinformatics used to advance human disease research

Novel virus entry mechanism could lead to new drugs against poxviruses

Novel virus entry mechanism could lead to new drugs against poxviruses

Immune system protein LL-37 critical in controlling replication of vaccinia virus

Immune system protein LL-37 critical in controlling replication of vaccinia virus

Potential therapeutic targets against serious side effects of smallpox vaccine

Potential therapeutic targets against serious side effects of smallpox vaccine

Cyclosporine suppresses hepatitis C virus and increases the chance of a sustained virological response after liver transplantation

Cyclosporine suppresses hepatitis C virus and increases the chance of a sustained virological response after liver transplantation

Gleevec or similar drugs might be useful in preventing adverse side effects of smallpox vaccine

Gleevec or similar drugs might be useful in preventing adverse side effects of smallpox vaccine

Vaccine targets tumors where they live

Vaccine targets tumors where they live

No serious adverse events found with next-generation smallpox vaccine

No serious adverse events found with next-generation smallpox vaccine

FDA approves new smallpox vaccination

FDA approves new smallpox vaccination

HHS awards contracts totaling more than $232 million to fund development of new vaccines against smallpox, plague and tularemia

HHS awards contracts totaling more than $232 million to fund development of new vaccines against smallpox, plague and tularemia

Discovery could pave the way to smallpox Immunity

Discovery could pave the way to smallpox Immunity

Double-punch approach to vaccine design more effective

Double-punch approach to vaccine design more effective

Research tests the efficacy of a smallpox vaccine candidate known as LC16m8

Research tests the efficacy of a smallpox vaccine candidate known as LC16m8

$20.7 million to make smallpox vaccine safer

$20.7 million to make smallpox vaccine safer

Alternative vaccine to Dryvax for smallpox

Alternative vaccine to Dryvax for smallpox

Experimental smallpox DNA vaccine

Experimental smallpox DNA vaccine

Scientists studying vaccinia virus, a relative of smallpox, have determined that a gene necessary for virus replication also has a key role in turning off inflammation

Scientists studying vaccinia virus, a relative of smallpox, have determined that a gene necessary for virus replication also has a key role in turning off inflammation